- Home
- PTGX vs ACLX Comparison
PTGX vs ACLX Comparison
Compare PTGX & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- ACLX
- Stock Information
- Founded
- PTGX 2006
- ACLX 2015
- Country
- PTGX United States
- ACLX United States
- Employees
- PTGX N/A
- ACLX N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- ACLX Health Care
- Exchange
- PTGX Nasdaq
- ACLX Nasdaq
- Market Cap
- PTGX 5.0B
- ACLX 4.4B
- IPO Year
- PTGX 2016
- ACLX 2022
- Fundamental
- Price
- PTGX $85.09
- ACLX $89.53
- Analyst Decision
- PTGX Strong Buy
- ACLX Strong Buy
- Analyst Count
- PTGX 9
- ACLX 9
- Target Price
- PTGX $86.44
- ACLX $117.78
- AVG Volume (30 Days)
- PTGX 991.5K
- ACLX 384.8K
- Earning Date
- PTGX 11-06-2025
- ACLX 11-05-2025
- Dividend Yield
- PTGX N/A
- ACLX N/A
- EPS Growth
- PTGX N/A
- ACLX N/A
- EPS
- PTGX 0.72
- ACLX N/A
- Revenue
- PTGX $209,217,000.00
- ACLX $35,898,000.00
- Revenue This Year
- PTGX N/A
- ACLX N/A
- Revenue Next Year
- PTGX $140.23
- ACLX $220.95
- P/E Ratio
- PTGX $118.80
- ACLX N/A
- Revenue Growth
- PTGX N/A
- ACLX N/A
- 52 Week Low
- PTGX $33.31
- ACLX $47.86
- 52 Week High
- PTGX $93.25
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- PTGX 69.75
- ACLX 58.26
- Support Level
- PTGX $76.70
- ACLX $84.50
- Resistance Level
- PTGX $80.43
- ACLX $90.30
- Average True Range (ATR)
- PTGX 2.93
- ACLX 3.88
- MACD
- PTGX 0.29
- ACLX -0.24
- Stochastic Oscillator
- PTGX 94.70
- ACLX 72.51
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.